查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
僵直性脊椎炎市場 - 成長、未來前景、競爭分析，2023-2031
市場調查報告書
商品編碼
1422211

僵直性脊椎炎市場 - 成長、未來前景、競爭分析，2023-2031

Ankylosing Spondylitis Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格

僵直性脊椎炎 (AS) 是一種慢性發炎性疾病，主要影響脊柱，導致疼痛、僵硬和運動障礙。在生物療法的進步、透過支持計畫以患者為中心的方法以及導致早期診斷的意識提高的推動下，強直性脊椎炎市場預計在2024 年至2032 年預測期內將以8.5% 的複合年增長率增長。然而，生物療法的高成本是一個重大的阻礙。市場區隔反映了對 AS 藥物的動態偏好和疾病盛行率的區域差異。從地區來看，北美對營收貢獻顯著，而亞太地區則顯示出強勁的成長潛力。競爭趨勢凸顯了Novartis、AbbVie和Janssen等大公司所採取的策略。這些公司利用技術創新、患者支援和全球市場擴張來保持競爭力。隨著僵直性脊椎炎市場從 2023 年發展到 2032 年的預測期，需要解決成本障礙，以確保持續成功地改善受這種慢性發炎性疾病影響的人們的生活。保持以患者為中心的方法和適應當地的細微差別。

生物製劑的進展

TNF抑制劑等生物製劑的進步極大地促進了這種疾病的治療。Cosentyx、Humira 和 Enbrel 等藥物已顯示出在減少發炎、控制症狀和改善 AS 患者整體生活品質方面的功效。臨床試驗和現實世界研究的證據顯示了這些生物療法的正面影響。例如，Cosentyx 的有效性已被證明可以持續改善 AS 症狀和功能。這些生物製劑仍然處於 AS 治療的最前沿，它們的持續開發和採用正在促進市場成長。

以病人為中心的方法和支持計劃

以患者為中心的方法，加上製藥公司提供的全面支持計劃，正在推動僵直性脊椎炎市場的發展。提供 AS 藥物的公司，如 Simponi、Remicade 和 Cimzia，已經啟動了支持計劃，幫助患者獲得藥物、管理副作用並遵守治療計劃。證據包括患者的感言和現實生活經歷，強調了這些支持計劃對治療依從性和患者結果的正面影響。隨著公司繼續優先考慮患者福祉和整體護理，以患者為中心的方法預計將在維持市場成長方面發揮關鍵作用。

提高認識和早期診斷

對僵直性脊椎炎的認識不斷提高以及早期診斷的努力正在對市場產生積極影響。醫療保健組織、患者權益團體和製藥公司的努力正在幫助提高人們對該疾病症狀和早期介入重要性的認識。這一點可以從診斷病例的增加和旨在早期發現 AS 的篩檢計劃的實施中看出。早期診斷可以及時介入並開始有效的治療，從而實現更好的疾病管理。隨著意識活動繼續對醫療保健專業人員和公眾進行教育，早期診斷的趨勢預計將持續存在並推動 AS 市場的成長。

生物製劑成本高

用生物製劑治療僵直性脊椎炎的高成本是進入市場的主要障礙。儘管 Cosentyx 和 Humira 等藥物有效，但它們給患者和醫療保健系統帶來了巨大的經濟負擔。證據包括強調生物治療的成本效益挑戰的經濟評估和研究。經濟負擔可能會限制某些患者的治療並阻礙最佳的疾病管理。儘管存在患者援助計劃，但解決生物製劑高成本這一首要問題對於確保公平獲得有效的僵直性脊椎炎治療至關重要。

藥物細分 Cosentyx、Humira 和 Enbrel 主導市場

2023年，僵直性脊椎炎市場銷售量最高的是Cosentyx、Humira、Enbrel等藥物。然而，Chimjia 在預測期內（2024-2032 年）的複合年增長率（CAGR）最高。這種動態成長是由患者和醫療保健提供者的獨特屬性和不斷變化的偏好所驅動的。Cimzia 在控制 AS 症狀和改善患者治療效果方面的有效性得到了研究和現實世界證據的支持。隨著僵直性脊椎炎治療模式的發展，受安全性和患者反應等因素的影響，藥物偏好可能會改變。

北美仍處於世界領先地位

按地區劃分，北美在 2023 年的銷售額中所佔份額最高，反映出其醫療基礎設施完善且普及率高。然而，預計亞太地區在預測期內的複合年增長率最高。這是基於亞太國家對 AS 認識的提高、獲得醫療保健的機會的改善以及治療方案的不斷發展。這些地理趨勢突顯出需要製定量身定制的策略來解決疾病流行、治療偏好和醫療保健基礎設施方面的區域差異。

預測期內市場競爭將加劇

2023年，僵直性脊椎炎市場的主要參與者包括Novartis, AbbVie, Janssen, Amgen, UCB, Pfizer, Eli Lilly & Company, Johnson & Johnson Services, Merck & Company等。這些公司採用不同的策略，包括研發、病患支援活動和市場拓展工作。新的治療方案、患者援助計劃以及與醫療保健專業人員和患者倡導團體的合作關係的持續發展證明了這一點。截至 2023 年，競爭格局顯示市場充滿活力，各公司都在努力增強其產品供應和支援結構。2023 年收入和預測期（2024-2032 年）揭示了競爭格局，其中技術創新、以患者為中心的方法和全球策略是成功的關鍵。

目錄

第一章 前言

  • 報告內容
    • 報告目的
    • 目標聽眾
    • 主要提供產品
  • 市場細分
  • 調查方法
    • 第一階段—二次調查
    • 第二階段-初步調查
    • 第三階段-專家評審
    • 先決條件
    • 採取的方法

第二章執行摘要

第三章僵直性脊椎炎市場：競爭分析

  • 主要供應商的市場地位
  • 供應商採取的策略
  • 主要產業戰略
  • 等級分析：2023 年 vs 2032 年

第四章僵直性脊椎炎市場：宏觀分析與市場動態

  • 介紹
  • 2022-2032年全球僵直性脊椎炎市場價值
  • 市場動態
    • 市場驅動力
    • 市場制約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析
  • 波特的五力模型
    • 供應商實力
    • 購買力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭對手之間的競爭
  • PESTEL 分析
    • 政局
    • 金融情況
    • 技術景觀
    • 法律狀況
    • 社會局勢

第五章僵直性脊椎炎市場：依藥物分類 2022-2032

  • 市場概況
  • 成長/利潤分析：2023 年與 2032 年
  • 2022-2032年數量和價格分析
  • 市場細分
    • cosentics
    • humira
    • Simponi
    • remicade
    • Enbrel
    • Cimzia
    • 其他

第 6 章 僵直性脊椎炎市場：依通路劃分 2022-2032 年

  • 市場概況
  • 成長/利潤分析：2023 年與 2032 年
  • 2022-2032年數量和價格分析
  • 市場細分
    • 醫院藥房
    • 零售藥店
    • 網上藥店

第7章北美僵直性脊椎炎市場2022-2032

  • 市場概況
  • 僵直性脊椎炎市場：依藥物分類 2022-2032
  • 僵直性脊椎炎市場：依分銷管道劃分 2022-2032
  • 僵直性脊椎炎市場：依地區劃分 2022-2032
    • 北美
      • 美國
      • 加拿大
      • 其他北美

第 8 章英國與歐盟僵直性脊椎炎市場 2022-2032

  • 市場概況
  • 僵直性脊椎炎市場：依藥物分類 2022-2032
  • 僵直性脊椎炎市場：依分銷管道劃分 2022-2032
  • 僵直性脊椎炎市場：依地區劃分 2022-2032
    • 英國和歐盟
      • 英國
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 歐洲其他地區

第9章亞太地區僵直性脊椎炎市場2022-2032

  • 市場概況
  • 僵直性脊椎炎市場：依藥物分類 2022-2032
  • 僵直性脊椎炎市場：依分銷管道劃分 2022-2032
  • 僵直性脊椎炎市場：依地區劃分 2022-2032
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 亞太其他地區

第10章拉丁美洲僵直性脊椎炎市場2022-2032

  • 市場概況
  • 僵直性脊椎炎市場：依藥物分類 2022-2032
  • 僵直性脊椎炎市場：依分銷管道劃分 2022-2032
  • 僵直性脊椎炎市場：依地區劃分 2022-2032
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第十一章中東和非洲僵直性脊椎炎市場2022-2032

  • 市場概況
  • 僵直性脊椎炎市場：依藥物分類 2022-2032
  • 僵直性脊椎炎市場：依分銷管道劃分 2022-2032
  • 僵直性脊椎炎市場：依地區劃分 2022-2032
    • 中東/非洲
      • GCC
      • 非洲
      • 其他中東/非洲地區

第十二章公司簡介

  • Novartis
  • AbbVie
  • Janssen
  • Amgen
  • UCB
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • 其他主要公司
Product Code: 140059-01-24

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine, causing pain, stiffness, and impaired mobility. The ankylosing spondylitis market is expected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2032, propelled by advancements in biological therapies, a patient-centric approach with support programs, and increasing awareness leading to early diagnosis. However, the high cost of biologic therapies poses a notable restraint. Market segmentation reflects the dynamic preferences for AS drugs and regional variations in disease prevalence. Geographically, North America contributes significantly to revenue, while the Asia-Pacific region presents high growth potential. Competitive trends highlight the strategies adopted by major players, including Novartis, AbbVie, and Janssen. These companies leverage innovation, patient support, and global market expansion to maintain a competitive edge. As the ankylosing spondylitis market progresses from 2023 to the forecast period of 2032, addressing cost barriers, sustaining patient-centric approaches, and adapting to regional nuances will be critical for continued success in improving the lives of individuals affected by this chronic inflammatory condition.

Advancements in Biologic Therapies

Advances in biologic therapies, such as TNF inhibitors, have significantly contributed to the treatment landscape of ankylosing spondylitis. Medications like Cosentyx, Humira, and Enbrel have shown efficacy in reducing inflammation, managing symptoms, and improving the overall quality of life for AS patients. The evidence lies in clinical trials and real-world studies that showcase the positive impact of these biological therapies. For instance, studies demonstrate the effectiveness of Cosentyx in achieving sustained improvement in AS symptoms and functionality. As these biologics continue to be at the forefront of AS treatment, their ongoing development and adoption contribute to the market's growth.

Patient-Centric Approach and Support Programs

A patient-centric approach, coupled with comprehensive support programs provided by pharmaceutical companies, has become a driving force in the ankylosing spondylitis market. Companies offering AS treatments, such as Simponi, Remicade, and Cimzia, have initiated support programs to assist patients in accessing medications, managing side effects, and adhering to treatment plans. The evidence lies in patient testimonials and real-world experiences that highlight the positive impact of these support programs on treatment adherence and patient outcomes. As companies continue to prioritize patient well-being and holistic care, the patient-centric approach is anticipated to play a pivotal role in sustaining the market's growth.

Increasing Awareness and Early Diagnosis

The growing awareness of ankylosing spondylitis and efforts to achieve early diagnosis have positively influenced the market. Initiatives by healthcare organizations, patient advocacy groups, and pharmaceutical companies have contributed to increased awareness about the disease's symptoms and the importance of early intervention. The evidence lies in the rise in diagnosed cases and the implementation of screening programs that aim to identify AS at an early stage. Early diagnosis allows for timely intervention and the initiation of effective treatments, leading to better disease management. As awareness campaigns continue to educate both healthcare professionals and the general public, the trend toward early diagnosis is expected to persist, fostering the growth of the AS market.

High Cost of Biologic Therapies

The high cost associated with biologic therapies for ankylosing spondylitis poses a significant restraint on market accessibility. Despite their effectiveness, medications like Cosentyx and Humira come with a substantial financial burden for both patients and healthcare systems. The evidence lies in economic evaluations and studies that highlight the cost-effectiveness challenges of biological treatments. The financial strain may lead to limited access for some patients, potentially hindering optimal disease management. While patient assistance programs exist, addressing the overarching issue of the high cost of biologics is crucial for ensuring equitable access to effective AS treatments.

Drug Segmentation: Cosentyx, Humira, and Enbrel Dominate the Market

In 2023, the ankylosing spondylitis market saw the highest revenue from drugs such as Cosentyx, Humira, and Enbrel. However, the highest Compound Annual Growth Rate (CAGR) during the forecast period (2024-2032) is anticipated from Cimzia. This dynamic growth is driven by the specific attributes and evolving preferences of patients and healthcare providers. Studies and real-world evidence support the efficacy of Cimzia in managing AS symptoms and improving patient outcomes. As the landscape of AS treatment evolves, drug preferences may shift, influenced by factors such as safety profiles and patient response.

North America Remains the Global Leader

Geographically, North America contributed the highest revenue percentage in 2023, reflecting the well-established healthcare infrastructure and high prevalence of ankylosing spondylitis cases. However, the Asia-Pacific region is poised to exhibit the highest CAGR during the forecast period. The evidence lies in the increasing awareness of AS, improving healthcare access, and the evolving landscape of treatment options in Asia-Pacific countries. These geographic trends emphasize the need for tailored strategies to address regional variations in disease prevalence, treatment preferences, and healthcare infrastructure.

Market Competition to Intensify during the Forecast Period

In 2023, major players in the ankylosing spondylitis market included Novartis, AbbVie, Janssen, Amgen, UCB, Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., and others. These companies adopted diverse strategies, including research and development, patient support initiatives, and market expansion efforts. The evidence lies in the continuous development of new treatment options, patient assistance programs, and collaborations with healthcare professionals and patient advocacy groups. As of 2023, the competitive landscape indicates a dynamic market where companies strive to enhance their offerings and support systems. Revenues for 2023 and the expected landscape for the forecast period (2024-2032) reveal a competitive environment where innovation, patient-centered approaches, and global strategies are key determinants of success.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofAnkylosing Spondylitis market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Ankylosing Spondylitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

    • Cosentyx
    • Humira
    • Simponi
    • Remicade
    • Enbrel
    • Cimzia
    • Others

Distribution Channel

    • Hospital pharmacy
    • Retail pharmacy
    • Online pharmacy

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Ankylosing Spondylitis market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Ankylosing Spondylitis market?
  • Which is the largest regional market for Ankylosing Spondylitis market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Ankylosing Spondylitis market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Ankylosing Spondylitis market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Ankylosing Spondylitis Market
  • 2.2. Global Ankylosing Spondylitis Market, By Drug, 2023 (US$ Million)
  • 2.3. Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 (US$ Million)
  • 2.4. Global Ankylosing Spondylitis Market, By Geography, 2023 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2023

3. Ankylosing Spondylitis Market: Competitive Analysis

  • 3.1. Market Positioning of Key Ankylosing Spondylitis Market Vendors
  • 3.2. Strategies Adopted by Ankylosing Spondylitis Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2032

4. Ankylosing Spondylitis Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Ankylosing Spondylitis Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Volume and Pricing Analysis, 2022-2032
  • 5.4. Market Segmentation
    • 5.4.1. Cosentyx
    • 5.4.2. Humira
    • 5.4.3. Simponi
    • 5.4.4. Remicade
    • 5.4.5. Enbrel
    • 5.4.6. Cimzia
    • 5.4.7. Others

6. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Volume and Pricing Analysis, 2022-2032
  • 6.4. Market Segmentation
    • 6.4.1. Hospital pharmacy
    • 6.4.2. Retail pharmacy
    • 6.4.3. Online pharmacy

7. North America Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 7.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 7.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

8. UK and European Union Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 8.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 8.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

9. Asia Pacific Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 9.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 9.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

10. Latin America Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 10.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 10.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

11. Middle East and Africa Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 11.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 11.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

12. Company Profile

  • 12.1. Novartis
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. AbbVie
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Janssen
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Amgen
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. UCB
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Pfizer, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Eli Lilly and Company
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Johnson & Johnson Services, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Merck & Co., Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Other Notable Players
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 2 Global Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 3 North America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 4 North America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 5 U.S. Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 6 U.S. Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 7 Canada Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 8 Canada Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 9 Rest of North America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 10 Rest of North America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 11 UK and European Union Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 12 UK and European Union Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 13 UK Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 14 UK Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 15 Germany Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 16 Germany Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 17 Spain Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 18 Spain Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 19 Italy Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 20 Italy Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 21 France Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 22 France Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 23 Rest of Europe Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 24 Rest of Europe Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 25 Asia Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 26 Asia Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 27 China Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 28 China Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 29 Japan Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 30 Japan Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 31 India Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 32 India Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 33 Australia Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 34 Australia Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 35 South Korea Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 36 South Korea Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 37 Latin America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 38 Latin America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 39 Brazil Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 40 Brazil Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 41 Mexico Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 42 Mexico Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 43 Rest of Latin America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 44 Rest of Latin America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 45 Middle East and Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 46 Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 47 GCC Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 48 GCC Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 49 Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 50 Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Ankylosing Spondylitis Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Ankylosing Spondylitis Market: Quality Assurance
  • FIG. 5 Global Ankylosing Spondylitis Market, By Drug, 2023
  • FIG. 6 Global Ankylosing Spondylitis Market, By Distribution Channel, 2023
  • FIG. 7 Global Ankylosing Spondylitis Market, By Geography, 2023
  • FIG. 8 Market Geographical Opportunity Matrix - Global Ankylosing Spondylitis Market, 2023

FIG. 9Market Positioning of Key Ankylosing Spondylitis Market Players, 2023

FIG. 10Global Ankylosing Spondylitis Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

  • FIG. 11 Global Ankylosing Spondylitis Market, By Drug, 2023 Vs 2032, %
  • FIG. 12 Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 Vs 2032, %
  • FIG. 13 U.S. Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 14 Canada Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 15 Rest of North America Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 16 UK Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 17 Germany Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 18 Spain Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 19 Italy Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 20 France Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 21 Rest of Europe Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 22 China Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 23 Japan Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 24 India Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 25 Australia Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 26 South Korea Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 27 Rest of Asia Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 28 Brazil Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 29 Mexico Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 30 Rest of Latin America Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 31 GCC Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 32 Africa Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 33 Rest of Middle East and Africa Ankylosing Spondylitis Market (US$ Million), 2022 - 2032